High uncertainty values would automatically flag cases with unusual or ambiguous immunophenotypic features for closer expert review, potentially improving the detection of CD5-negative lymphoproliferative disorders and other non-CLL neoplasms that currently challenge the DNN. This evidence concerns the gene CD5 and lymphoproliferative syndrome.